Zydus Wellness Ltd (ZYDUSWELL) is currently trading at 504.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Zydus Wellness is an Ahmedabad-headquartered integrated health and wellness consumer company that develops, manufactures and markets functional FMCG products across nutrition, personal care and packaged foods, owning flagship Indian brands such as Complan, Glucon-D, Sugar Free, Nutralite, Everyuth, Nycil and the acquired RiteBite and Comfort Click portfolios into international VMS. In Q1 FY27 Zydus Wellness reported consolidated net sales of INR 14,299 million, a robust 66.7% year-on-year growth driven by consolidation of Comfort Click and strong portfolio momentum; EBITDA rose 55.3% to INR 2,417 million while reported net profit fell 7% due to amortisation of acquired brands, but excluding amortisation net profit grew 26.5%. The company’s international business, including Comfort Click, grew like-for-like by 24.8% while domestic growth was 4.6%; organised channel saliency reached an industry-leading 38% with digital commerce at about 21% and modern trade at 17%, highlighting a structural shift toward quick commerce and e-commerce as primary engines of growth. Comfort Click consolidation is already EPS-accretive and materially higher-margin, and management is actively building direct-to-consumer and marketplace presence in the U.S. and Middle East; Zydus Wellness is leveraging technology, analytics and AI-driven consumer engagement to premiumise its portfolio and scale new product formats such as Complan RTD and VieMax Diabetes Care. Seasonality remains a visible risk: a softer summer due to unseasonal rains hit Nycil and some food brands, reducing summer portfolio sales by 12%, but management reports recovery signs and a diversified portfolio that reduces dependence on seasonal demand and supports steadier growth across the fiscal year.

Over the past 52 weeks, Zydus Wellness Ltd has traded between a low of ₹357.55 and a high of ₹610.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Zydus Wellness Ltd has a market capitalization of approximately 16,383.69. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Zydus Wellness Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 87.05 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 16,383.69 Cr, Zydus Wellness Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Zydus Wellness Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Zydus Wellness Ltd is 87.05. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Standalone net sales in March 2026 were ₹132.6 crore, up 71.1% year-on-year from ₹77.5 crore in March 2025.

Zydus Lifesciences raised the buyback price to ₹1,260 per equity share from the earlier ₹1,150 per share.

The company reported consolidated net sales of INR 8,577 million in Q1 FY26, with net sales growth of 2.2% year on year.

Revenue rose 16.2% to ₹7,587 crore, EBITDA increased 20.2% to ₹2,554 crore, and EBITDA margin expanded to 33.7% from 32.6%.